$44.35
-0.09-0.2%
Last update: Oct 27, 7:11 AM
Alkermes PLC (ALKS) Stock Price, Quote, News & History
ALKSNASDAQ
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.
You can purchase shares of Alkermes (NASDAQ:ALKS) through any online brokerage.
Other companies in Alkermes’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Alkermes has a consensus price target of $52.63.
The stock price for Alkermes (NASDAQ: ALKS) is $44.35 last updated October 27, 2026 at 7:11 AM EDT.
There are no upcoming dividends for Alkermes.
Alkermes does not have any upcoming earnings scheduled.
There is no upcoming split for Alkermes.
Alkermes is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to...
